![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PAVmed Earns CE Mark for Esophageal Cancer Test
PAVmed Earns CE Mark for Esophageal Cancer Test
June 14, 2021
PAVmed subsidiary Lucid Diagnostics has obtained CE mark certification for EsoGuard, a DNA test used to detect esophageal cancer.
The molecular diagnostic, which tests esophageal cells gathered using the company’s noninvasive cell-collection device, is designed to screen at-risk chronic heartburn patients early on for esophageal precancer and cancer.
EsoGuard is the first commercially available diagnostic test that could be used as a widespread screening tool for esophageal cancers, the company said, adding that the test was shown to be “highly accurate” in a 408-patient trial.
Upcoming Events
-
21Oct